Why Mirum Pharmaceuticals (MIRM) Is Up 13.3% After Raising 2025 Revenue Guidance and Filing Shelf Registration

• In early August 2025, Mirum Pharmaceuticals reported its second quarter and six-month results, highlighting year-over-year revenue growth to US$127.79 million for the quarter and a narrowed net loss of US$5.86 million, alongside raising its full-year 2025 revenue guidance to between US$490 million and US$510 million; it also filed a new US$200 million shelf registration covering common and preferred stock, debt securities, and warrants.
• The improved guidance and earnings results suggest that Mirum’s recent growth initiatives and expanding rare disease portfolio may be gaining traction, potentially accelerating the company’s business momentum ahead of new product launches and international expansion efforts.
• With Mirum Pharmaceuticals boosting its full-year revenue expectations, we will now assess how this signals a potentially shifting investment narrative for the company.

The end of cancer? These 26 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

Mirum Pharmaceuticals Investment Narrative Recap

To be a shareholder in Mirum Pharmaceuticals, you need to believe in the potential for rare disease therapies to deliver sustainable, above-market revenue growth despite heavy reliance on a single product and constant R&D investment. The recent filing of a US$200 million shelf registration does not materially alter the most important short-term catalyst, which remains the clinical and commercial progression of the late-stage pipeline, nor does it reduce the key risk of revenue concentration in Livmarli.

The company’s raised full-year revenue guidance, now set between US$490 million and US$510 million, is particularly relevant as it signals management’s confidence in growing patient reach and accelerating product adoption. This development aligns with the broader catalyst of expanding addressable markets, but sustained momentum hinges on additional clinical data and potential regulatory approvals supporting future portfolio diversity.

However, investors should also be aware that, in contrast to these promising signals, the company’s exposure to reimbursement setbacks in new international markets remains a critical area for...

Read the full narrative on Mirum Pharmaceuticals (it's free!)

Mirum Pharmaceuticals is projected to achieve $794.3 million in revenue and $102.1 million in earnings by 2028. This outlook is based on an assumed annual revenue growth rate of 22.8% and represents a $160.7 million increase in earnings from the current level of -$58.6 million.

Uncover how Mirum Pharmaceuticals' forecasts yield a $78.27 fair value, a 15% upside to its current price.

Exploring Other Perspectives

Four community fair value estimates for Mirum Pharmaceuticals range widely from US$34.86 up to US$225.51 per share. With so many viewpoints from the Simply Wall St Community, keep in mind that expanding patient populations and new clinical data could have a significant effect on future growth potential.

Explore 4 other fair value estimates on Mirum Pharmaceuticals - why the stock might be worth 49% less than the current price!

Build Your Own Mirum Pharmaceuticals Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Mirum Pharmaceuticals research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Mirum Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mirum Pharmaceuticals' overall financial health at a glance.

Ready For A Different Approach?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com